FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:1402-1405 April 3, 2003 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Koutsky, L. A. Related Article by Stanberry, L. R. PubMed Citation

To the Editor: Koutsky et al. (Nov. 21 issue)¹ report the results of a primary efficacy analysis in a controlled trial of human papillomavirus type 16 (HPV-16) vaccine that includes less than two thirds of all randomized study subjects. To better ascertain the comparability of the two study groups, we are interested in knowing the balance of other risk factors for cervical cancer, such as socioeconomic status, seropositivity for the human immunodeficiency virus (HIV), and use of oral contraceptives. In addition, the investigators excluded a substantial high-risk group (those who reported more than five male sex partners during their lifetime) . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.